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Subacute Measles Encephalitis:  The neurological sequelae of the measles outbreak 
in South Africa 
 
Introduction  
A measles outbreak occurred in South Africa between 2009 and 2011 with 18 699 
confirmed cases.  This highly contagious virus can affect the central nervous system 
in many ways.  Early in the disease course there may be direct viral involvement as a 
primary measles encephalitis or indirectly as an inflammatory immune mediated 
demyelinating meningoencephalitis.  Latent infections are rare and may manifest in 
two ways:  years later as subacute sclerosing panencephalitis (SSPE) caused by viral 
persistence in a seemingly immunocompetent host or months later as subacute 
measles encephalitis (SME) in an immunocompromised host.  SME is characterised 
by seizures, typically epilepsia partialis continua, and altered mental status and 
carries a high mortality.  It is an elusive diagnosis and usually confirmed on brain 
biopsy.  
 
Patients and results   
Eight patients were diagnosed with SME between July and October 2010 at our 
tertiary referral hospital.  All patients were HIV positive, with a median CD4 
lymphocyte count of 37 cells/µl (range 1 to 268).  All patients had epilepsia partialis 
continua during the course of the illness and other common features included 
encephalopathy, visual loss, hearing loss, and generalised seizures.  Strikingly, 
cerebrospinal fluid (CSF) examination was normal in all patients and computed 
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tomography (CT) Brain imaging was normal in all but one patient.  Magnetic 
resonance imaging (MRI) Brain demonstrated superficial and deep grey matter 
abnormalities in the majority of patients with contiguous cortical spread over weeks 
documented in one patient.  Electroencephalograms (EEGs) showed periodic 
epileptiform discharges in seven patients.  Diagnosis was confirmed by brain biopsy 
in one patient, by post-mortem examination in three patients and by supportive 
laboratory findings (positive measles PCR and/or measles antibodies in urine or CSF) 
in the remainder.  The outcome was fatal in seven of the cases with a median time to 
death of 3 weeks.  
 
Conclusion  
South Africa has the greatest number of people living with HIV:  12.6% of the 
population (6·4 million people) are infected.  This is the largest SME case series to 
date and is seen in the aftermath of a measles outbreak in South Africa.  
Immunocompromised patients are clearly susceptible and typically present with 
epilepsia partialis continua and rapid decline in neurological functioning and death 
ensuing within a month in the majority of cases.  MRI T2-weighted signal changes in 
the cortical grey matter, are typical.  In the absence of a brain biopsy, we propose 
the use of measles virus PCR in urine and CSF.  The importance of herd immunity, by 
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South Africa has 6·4 million South Africans, or 12·6% of the total population, 
living with HIV (1), making our population particularly vulnerable to opportunistic 
infections.  South Africa experienced a measles outbreak that started in late 2009 
and lasted until early 2011.  There was a marked increase in cases of measles, with 
the highest incidence reported in March 2010.  Between January 2009 and 
September 2011 a total of 18 699 new measles cases had been reported to the 
National Institute of Communicable Diseases (2).  A mass vaccination campaign was 
instituted in mid-April to early May 2010, resulting in a significant decline in new 
measles cases after this period. 
  
The measles virus is highly contagious, and outbreaks are fuelled by overcrowding 
and poor vaccine coverage, making elimination status in South Africa difficult to 
attain.  Measles may infect the central nervous system (CNS) as primary measles 
encephalitis (an acute viral encephalitis), or result after 2 - 4 weeks in a post-
infectious immune-mediated inflammatory disorder or acute disseminated 
encephalomyelitis (ADEM).  There are two further rare and latent CNS complications 
resulting from a preceding measles infection: subacute sclerosing panencephalitis 
(SSPE) caused by years of viral persistence in a seemingly immunocompetent host, 
and subacute measles encephalitis (SME), also referred to as measles inclusion body 
encephalitis (MIBE), occurring in an immunocompromised host (3).  SME manifests a 
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few months after the acute measles infection.  Patients present with seizures, often 
epilepsia partialis continua, and altered mental status.  It carries a mortality rate of 
85% and survivors often have significant neurological impairment.  SME has hitherto 
only been described in single case reports as a rare complication of measles in the 
context of organ transplantation, immunosuppressive therapy, primary  
immunodeficiencies, and HIV/AIDS (4–12).  We diagnosed eight HIV-infected 
patients with SME as they presented to a tertiary referral hospital between July and 
October 2010. 
 
2. Research justification 
South Africa has the greatest number of people infected with HIV and the highest 
number of new cases annually (13).  In this context, the outbreak of a highly 
contagious virus is likely to have significant consequences for its residents.  The 
devastating nature of SME and the difficulty in diagnosing the condition were 
important factors that prompted us to disseminate knowledge regarding this 
otherwise rare disease.   
 
3. Objectives 
By publishing our findings in the form of a case series in a nationally relevant journal, 
we aimed to create awareness and recognition of SME; improve time to diagnosis; 
assist physicians in managing patients and counselling families; and emphasise the 




All patients referred to our Neurology Division with suspected SME were assessed 
and special investigations performed on a case by case basis.  However, baseline 
demographic details, HIV status, CD4 count, anti-retroviral therapy status, 
cerebrospinal fluid (CSF) biochemistry and cell count, EEG and neuroimaging 
(computed tomography (CT) or magnetic resonance imaging [MRI]) were 
documented in all patients with patient identifiers anonymised on a data collection 
form.  Additional tests included serum, urine and CSF measles PCR; serum and CSF 
measles antibody titres, brain biopsy or post-mortem brain histology.  See data 
collection form in Part D: Appendix 1.  We classified patients as having ‘definite 
SME’ in the presence of a suggestive clinical picture (focal seizures and/or 
encephalopathy) and a positive measles PCR in either tissue from a brain biopsy, CSF 
or urine.  ‘Probable SME’ was diagnosed in the context of a suggestive clinical 
picture, normal CSF findings in the absence of other identifiable pathogens, and with 
supportive features such as MRI demonstrating multifocal grey matter signal 
abnormalities and/or positive CSF measles serology (IgG).   Consent was obtained 
from the family of our index patient.  See Consent form in Part D:  Appendix 2. 
 
5. Ethics committee approval  
Human Research Ethics committee approval was obtained, HREC REF 487/2010.  See 
Part D: appendix 3. 
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6. Dissemination of findings 
Our case series was published in the South African Medical Journal (SAMJ) in May 
2011.  Our findings were also presented at the Groote Schuur Hospital/UCT 
Department of Medicine Thursday Forum in the same year.  I presented our patients 
at the annual Neurological Association of South Africa (NASA) meeting in Durban in 
March 2011.  In October 2011, I delivered a platform presentation at the annual 
Association of British Neurologists (ABN) meeting in Newcastle in the UK.   
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PART B:  STRUCTURED LITERATURE REVIEW 
Objectives of literature review. 
A.  To obtain background information regarding the pathophysiology of measles and 
how the measles virus affects the Central Nervous System (CNS). 
B.  To perform a detailed review of subacute measles encephalitis (SME), reporting 
published information regarding risk factors, clinical presentation, special 
investigations, treatment and outcome. 
C.  To understand the pathogenesis of SME in HIV infected patients following the 
measles outbreak in South Africa in 2009-2010. 
 
Literature search strategy. 
For general background information regarding a review of measles and its CNS 
complications, Pubmed, Medline and Google Scholar were searched using keywords 
“measles review”, “measles encephalitis”, “measles central nervous system”, 
“subacute measles encephalitis”, “measles inclusion body encephalitis”. 
For the detailed literature review regarding SME, I searched Pubmed and Medline 
databases, using the following keywords, MeSH terms and Boolean operators: 
“Subacute measles encephalitis”, “immunosuppressive measles encephalitis”, 
“measles inclusion body encephalitis”, “measles encephalitis AND (subacute OR 
inclusion OR immunosuppressive) NOT sclerosing”. 
A hand search of selected articles’ bibliography was also performed. 
For information regarding the measles outbreak in South Africa, the National 
Institute of Communicable Diseases website (www.nicd.ac.za) was accessed.  
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Inclusion criteria:  Relevant papers available in English were reviewed.  Full text 
articles were sourced via the University of Cape Town library server.  
Exclusion criteria:  the Boolean operator “NOT sclerosing” was used to limit articles 
referencing subacute sclerosing panencephalitis.   
 
Quality and relevance criteria   
Studies were reviewed relating to human subjects with subacute measles 
encephalitis with heavier weighting given to case reports with histological 
confirmation of diagnosis on brain biopsy or post-mortem specimens.  Articles 
relating to primary or post-infectious measles encephalitis and SSPE were excluded. 
 
Summary and interpretation of literature review  
1. Overview of the pathophysiology of measles and how the measles virus affects 
the Central Nervous System  
The measles virus (MV) is a spherical, enveloped, non-segmented, single-stranded, 
negative-sense RNA virus and a member of the Morbillivirus genus in the 
Paramyxoviridae family (14).  Six proteins are found in the virion (see Fig. 1). The 
envelope has surface projections composed of the viral hemagglutinin (H) and fusion 
(F) glycoproteins with the matrix (M) protein lining the interior.  Within this 
envelope, the nucleocapsid is found, formed by the genomic RNA wrapped in the 
nucleocapsid (N) protein and packed in the form of a symmetrical coil with the 
phosphoprotein (P) and large polymerase (L) proteins attached (15).    
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Figure 1: The enveloped measles virion demonstrating its six proteins 
From:  Measles virus, immune control, and persistence. Griffin DE et al. FEMS Microbiol Rev. 2012  
 
The two originally identified cellular receptors for MV were CD46 and CD150 
(signalling lymphocyte activation molecule [SLAM]).  CD46 is a complement 
regulatory molecule that is ubiquitously expressed on all nucleated cells while SLAM 
is expressed on activated T and B lymphocytes and antigen-presenting cells (in 
concordance with the lymphotropism of measles virus), but has not been found on 
epithelial, endothelial, and neural cell types (16).  More recently, poliovirus receptor- 
related 4 (PVRL4) or nectin-4 was described and functions as an adherence junction 
protein of the immunoglobulin superfamily and is expressed on airway epithelial 
cells (17).  SLAM was identified as receptor for both vaccine and wild-type MV strains 
whereas CD46 acts as cellular receptor only for vaccine strains (18).  It has therefore 
been suggested that other yet unknown molecules act as receptors for MV in the 
CNS or that the MV may gain entry into the CNS through cerebral endothelial cells or 
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infected monocytes (3).  In a fibroblast environment, MV results in a highly 
productive infection that causes cytolysis, giant cell formation, and high titers of 
extracellular virus.  In the neuron, in contrast, despite the spread of virus, there is 
little evidence of MV-induced cell death, syncytium formation, or infectious virus 
production.  Electron microscopy (EM) analysis has shown that viral budding does 
not occur from the neuronal surface, although nucleocapsids are present in the 
cytoplasm and aligned at the cell membrane.  See Figure 2.  There is no evidence of 
fusion between infected cell bodies, but because of the presynaptic nucleocapsid 
localisation, it is likely that MV can spread between neurons via synaptic connections 
in the absence of cell fusion and may not require a MV receptor to maintain a 
persistent neuronal infection (19).  
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Figure 2:  Incomplete budding at surface of MV-infected neurons. Primary CD46+ neuron cultures were 
infected with MV Edmonston (MOI = 1) or mock infected, fixed at 3 d.p.i. with glutaraldehyde, and 
processed for EM. (A) Two adjacent neuronal cell bodies containing cytoplasmic fuzzy nucleocapsids 
(MV) but few buds at the cell surface. Arrows indicate intact cell membranes separating the two cells. 
Magnification x 7,560. Bar = 2 um. (B) Higher magnification of infected neuron shows 
smooth nucleocapsid alignment at the cell surface, but only at the immature stage of budding. 
Magnification x 96,600. Bar = 200 nm. Closed large arrows, cross-sectional view of nucleocapsid; open 
large arrow, longitudinal view of nucleocapsid; N, nucleus; M, mitochondria; R with small arrows, 
ribosomes 
 
From:  Measles Virus Spread between Neurons Requires Cell Contact but Not CD46 Expression, 
Syncytium Formation, or Extracellular Virus Production. DMP Lawrence  et al. J Virol 2000 
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This dramatic change in the mechanism of viral spread in the brain as opposed to a 
fibroblast environment may be due to a property of the neurons rather than to the 
accumulation of viral mutations.  The paucity of neuronal cell death following MV 
infection suggests that this may be a protective strategy by the neuron to safeguard 
itself against cytolytic MV replication (19).   
 
Although RNA viruses typically have high mutation rates, the MV is thought to be an 
antigenically monotypic virus.  Neutralising epitopes on the haemagglutinin protein 
are highly conserved and this fortuitously means that attenuated measles vaccines 
that were developed decades ago from a single MV genotype remain protective 
worldwide today (14). 
 
Measles is a highly contagious, directly transmitted pathogen and spreads via 
contaminated respiratory droplets.  Outbreaks can occur in populations in which 
fewer than 10% of people are susceptible (20).  Eradication is possible though as 
latent measles virus infections do not result in prolonged contagiousness and there 
are no animal reservoirs that maintain virus transmission; MV infection can 
therefore only be maintained by an unbroken chain of acute infections (14). 
 
Adaptive cellular immunity is generally regarded as most important for the clearance 
of MV as patients with agammaglobulinemia recover from infection, while those 
with defects in cellular immunity (e.g. HIV infection, congenital immune deficiency, 
transplant immune suppression) are prone to develop severe disease (15).  The 
antiviral immune response is effective in clearing virus and in establishing long-term 
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resistance to reinfection but is associated with paradoxical immune suppression and 
increased susceptibility to other (non-measles) antigens for weeks after the rash 
(21). 
 
Following an incubation period of about 10 days, clinically apparent measles begins 
with a prodromal illness characterised by fever, cough, coryza, and conjunctivitis. 
Characteristic Koplik’s spots—small white lesions on the buccal mucosa—might be 
visible during the prodrome.   A few days later, the erythematous and maculopapular 
rash appears, starting on the face and behind the ears and then spreading to the 
trunk and extremities (14).  Complications occur most frequently in the respiratory 
tract, commonly pneumonia and laryngotracheobronchitis.  Diarrhoea and 
keratoconjunctivitis are other known complications (14). 
 
Although CNS involvement is rare, it is the most common cause of longterm 
sequelae and is a relatively common cause of death, second only to lower 
respiratory tract complications (22).  Encephalitis was diagnosed in 0.1% of patients 
reported with measles in the United States of America from 1987–2000 (22).  A 
series from Germany consisting of  96 children hospitalised with measles, found 
measles encephalitis in two children, both with a fatal outcome (23).  An Iraqi 
hospital based review of measles complications reported encephalitis in 2% of 
patients, accounting for 16.6% of deaths (24).   
 
The measles virus can affect the CNS in one of four ways:  primary measles 
encephalitis (PME), acute postinfectious measles encephalomyelitis (APME), 
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subacute measles encephalitis (SME), also termed measles inclusion body 
encephalitis (MIBE) and subacute sclerosing panencephalitis (SSPE).  For the purpose 
of this dissertation, the term SME is favoured over MIBE as I find it more useful as a 
clinical descriptor of the illness rather than the histopathological term MIBE.  
  
PME is a direct viral infection of the brain which occurs at the exanthem phase of the 
disease and affects 1-3 per 1000 patients with measles infection.  MV RNA can be 
isolated from the brain and CSF during this stage.  Ten to 15 percent of patients will 
die, and an additional 25% will be left with permanent neurologic deficits (3).   
 
APME is an immune mediated disorder which does not involve direct viral infection 
of the brain and occurs in 1 per 1000 measles infections.  It is also termed measles- 
induced acute disseminated encephalomyelitis (ADEM) and is primarily a post-
infectious demyelinating disease which occurs during the resolving phase of the 
exanthem or even a few weeks following the rash (3).  The goal of treatment is to 
dampen the immune response and corticosteroids, intravenous immunoglobulin 
and/or plasmapheresis have been used with success (3).   It should be noted that 
PME and APME may be part of an overlapping spectrum, as the clinical picture and 
time to onset of symptoms may be similar.  A series of 12 children who presented 
with neurological symptoms 2-7 days following the measles rash were reported (25).  
Eight of these patients had abnormal MRI neuroimaging:  four demonstrated white 
matter changes consistent with a demyelinating process while four had 
predominantly gray matter involvement.  Interestingly, the patients with gray matter 
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changes had a poorer outcome and it is postulated that in these patients direct viral 
invasion was playing a role (25).   
 
SME is an opportunistic CNS infection in immunocompromised hosts where the MV 
cannot be contained and presents within months following measles infection.  A 
detailed review of SME follows in section 2.   
 
SSPE is another devastating complication of measles infection occurring in 
approximately one in 10 000 children (14).  It primarily affects immunocompetent 
children with symptoms developing 6-15 years after measles infection (3).  The 
incidence of SSPE inversely correlates with rates of measles vaccination (26).  
Children who contract measles before the age of 1 year are at greatest risk of later 
developing the disease.  The antibody response to MV is accentuated with significant 
production of MV-specific antibody in the CSF.  Thus, although present, the immune 
response is ineffective in clearing virus from the CNS.  Frequent U to C changes 
suggest that mutation of viral RNA by adenosine deaminase (biased or A/I 
hypermutation) is occurring in persistently infected cells.  There is a lack of budding 
of virus and therefore infectious virus cannot usually be recovered from the CNS.  
This in turn may be caused by mutations that accumulate in the genes for the M, F, 
and H envelope proteins which interfere with assembly and budding (15).  It is not 
known whether these mutations facilitate spread within the CNS and are necessary 
for viral persistence or whether they accumulate because of the lack of selective 
pressure to maintain envelope functions during replication in the CNS, seeing as the 
virus can spread transsynaptically without production of infectious virus (15). 
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Initial symptoms of SSPE include behavioural changes and cognitive decline.  Within 
weeks or months these symptoms become more obvious and motor dysfunction 
develops with typically myoclonic seizures.  About half of affected patients will also 
develop ocular complications in the form of necrotising retinitis (3).  There are high 
titres of measles antibody in the CSF and characteristic long latency periodic 
complexes on EEG (27).  Death usually follows the onset of symptoms within 3 years 
(28).  Treatment with isoprinosine and ribavirin, immunoglobulin therapy and 
interferons have been tried without sustained benefit (3).   The rationale for using 
alpha-interferon therapy is that the cerebrospinal fluid interferon levels are low in 
patients with SSPE and exogenous administration of interferon possibly suppresses 
viral replication and enhances the body’s immune system (29).  However, an 
international multicentre study performed by the International Consortium on 
Subacute Sclerosing Panencephalitis, found no significant differences in the survival 
rates or morbidity between groups randomized to treatment with either oral 
isoprinosine (Inosiplex) alone versus combined treatment of isoprinosine and 
intraventricular interferon-alpha (30).   
 
2. Subacute measles encephalitis  
SME is an opportunistic CNS infection in immunocompromised patients infected with 
measles.  It typically presents a few months following the initial infection, although it 
may be difficult to date accurately as many of these patients do not mount a 
significant T-cell response and therefore the skin rash may be absent.  By 1993, there 
were 31 patients reported in 16 case reports and summarised in the literature (4).  In 
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short, the findings were:  mean age of 6.1 years (range 2-21 years); 70% of patients 
had a history of clinical measles with a latent period ranging from one to seven 
months; the most common presentation was seizures and altered mental status with 
one third of patients fulfilling criteria for epilepsia partialis continua; the majority of 
CSF analyses were normal; only a few patients had elevated serum and/or CSF 
measles antibody titres at presentation; EEG was abnormal in all patients tested; CT 
Brain was normal at presentation; neuropathology demonstrated varying 
combinations of inflammatory and necrotic changes with intranuclear viral 
inclusions, tubular structures consistent with paramyxovirus nucleocapsid and PCR 
positivity;  treatment consisted of supportive measures in all and specific antiviral 
therapy in four patients;  outcome was poor with 85% mortality and moderate to 
severe neurological impairment in survivors.  Since this literature review of 1993, at 
least nine further cases have been described in eight case reports in the English 
literature.  These more recent findings are summarised below (note that this review 
excludes our subsequent publication about SME in South Africa (36), see Part C:  
Publication format). 
 
2.1. At risk populations 
SME has been described in immunocompromised patients secondary to solid organ 
transplant (11,12), stem cell transplant (9), haematological malignancy (particularly 
acute lymphoblastic leukaemia)(4,6), auto-immune disease (ankylosing 
spondylitis)(10), primary immune deficiencies (5) and HIV infection (4,7).   
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In one case, SME followed on vaccination in a young boy with a primary immune 
deficiency where the vaccine strain was sequenced from brain tissue (5).  There has 
been some concern regarding the use of live attenuated vaccines in HIV infected 
individuals and the American Academy of Paediatrics issued guidelines to withhold 
administration of the measles vaccine to severely immunosuppressed HIV infected 
children (as defined by CD4+ lymphocyte counts for different age groups)(31).  In 
South Africa, HIV infected children can be immunised against measles only if they 
otherwise healthy without symptoms of an opportunistic infection.  (32).   
 
There has been a report of SME in an apparently immunocompetent 43 year old man 
who died a month after neurological presentation and had positive measles 
histology and PCR on brain biopsy (8).  He presented with cognitive slowing, visual 
loss and headache.  He subsequently became obtunded with hemiplegia and 
myoclonic jerks and demised 36 days after presentation.  His CSF showed a 
lymphocytosis with oligoclonal bands and high CSF and serum measles antibody 
titres.  MRI T2 weighted images showed increased signal in the subcortical and deep 
white matter of the right occipital and left tempero-occipital lobes.  Histological 
examination confirmed a meningoencephalitis and paramyxovirus was seen on EM 
with measles RNA present.  Analysis of matrix gene sequences did not demonstrate 
the typical U to C hypermutations and did not resemble the known SSPE virus 
strains.  This is the only reported SME case occurring in an immunocompetent 
patient and demonstrates the overlapping area between SME and a fulminant form 
of SSPE.  The myoclonic jerks, high titres of measles antibodies in the CSF, white 
matter changes on MRI and his immunocompetent state, would favour fulminant 
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SSPE.  However, the rapid clinical decline, older age at presentation and histological 
findings are more typical of SME. 
 
2.2. Clinical presentation 
The most common presentation is with focal motor seizures, often continuous 
(5,6,9–12).  Other presentations include hemiparaesthesiae, hemiballismus (7), 
cortical visual loss (8) and cognitive slowing (6).  Myoclonus, choreiform movement 
(6), hemianopia (10) and hemiplegia (10,12) is described during the course of the 
illness.  Over days to weeks there is an associated decrease in the level of 
consciousness with seizures responding poorly to anti-epileptic drugs (5,6,9–12).   
The latent period to presentation could only be ascertained in three patients:  two 
who had a rash one (10) and four (11) months, respectively, prior to presentation 
and one who was vaccinated eight months prior (and was confirmed to be infected 
with vaccine strain)(5).  The remaining patients had no rash or clear measles ictus.  
 
2.3. Special investigations   
2.3.1. Cerebrospinal fluid 
Two patients had lymphocytic responses in their CSF (8,9), while all other patients 
had normal CSF biochemistry and cell counts (5–7,10–12).  Measles CSF IgG is often 
positive, but CSF IgM was weakly positive in only one case (10) and there is only 
documentation of CSF measles PCR being performed in one patient: this patient 




All patients had neuroimaging performed in the form of MRI and although findings 
are not reported in a standardised way, all MRIs were abnormal at some stage of the 
disease, albeit not always in the early stages of the disease.  Common findings 
include  high signal lesions on T2-weighted images or fluid-attenuated inversion 
recovery (FLAIR) sequences involving the cortical ribbon (5,6,8–11) with frequent 
involvement of the thalamus (7,12) and basal ganglia (6,9).  In patients where serial 
imaging was performed, lesions became more widespread over time (9). Contrast 
enhancement was reported in one patient (10). 
 
2.3.3. EEG 
EEG is abnormal in the majority of patients with findings ranging from periodic 
lateralised epileptiform discharges to diffuse slowing to focal status epilepticus (5,9–
11). 
 
2.3.4. Histological investigations 
In six of the patients, brain biopsy and/or post-mortem studies of the brain were 
performed.  Common findings were inflammatory changes consistent with a 
meningoencephalitis, the presence of intranuclear viral inclusions and visualisation 
of the paramyxovirus nucleocapsid on EM (5–10).  Measles specific antibodies 
reacted with antigen in one case (6), whereas MV RNA was found using PCR 




Patients were treated with varying combinations of anti-epileptic drugs, 
corticosteroids, Aciclovir, intravenous Immunoglobulin and Ribavirin.  Two cases 
were reported of children with acute lymphoblastic leukaemia, aged three and four 
years respectively, who were given intrathecal interferon therapy (33,34).  In both 
cases the interferon therapy halted progression, but the first patient died a month 
later from a leukaemia relapse while the second child was left with severe disability. 
 
2.5. Outcome 
The outcome was documented for seven of the nine patients.  The outcome was 
fatal in six patients (5,7–10) with the remaining patient being stable but severely 
impaired in a vegetative state (6). 
 
3. The pathogenesis of SME in the context of the measles outbreak in South Africa 
in 2009/2010 
The most detailed molecular virological description of SME in HIV infected patients 
comes from the Department of Virology at Groote Schuur Hospital, University of 
Cape Town (35).  This description stemmed from our series of patients through 
collaboration with Dr Diana Hardie at the Department of Virology.   
 
The most recent measles outbreak in South Africa was from 2009-2011 with 18 699 
deaths reported (36).  A mass vaccination campaign from April to May 2010 resulted 
in a significant decline in new measles cases (37).  See Figure 3.  This is part of a 
worrying trend of measles outbreaks in Africa.  In 2008, only two countries had more 
than 1000 reported measles cases, but in 2010 a total of 16 countries had in excess 
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of this number.  See Figure 4.  South Africa was second only to Malawi in terms of 
numbers of reported cases with 24 393 affected patients (14). 
 
Figure 3: Measles IgM positive results per province: South Africa, January 2009 - 8 February 2011 
 
From:  Communicable Disease Communique, February 2011 
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Figure 4: Confirmed cases of measles reported to WHO from countries that participated in measles 
surveillance in Africa in 2008, 2009, and 2010. 
Countries with more than 1000 cases of measles reported to the WHO from 46 countries that 
participated in measles surveillance in Africa in 2008, 2009, and 2010 are shown in blue. Reported 
measles cases include cases confirmed clinically, by laboratory testing, or by epidemiological linkage. 
Countries with fewer than 1000 confirmed cases of measles reported to the WHO in 2008 and 2009 
that had more than 5000 confirmed cases of measles in 2010 are shown in white. 
 
From:  Measles. Moss WJ et al. Lancet. 2012 Jan 14; 379(9811):153–64 
 
Measles virus does not usually replicate extensively in brain tissue and it is thought 
that key mutations are required to confer a neurovirulent phenotype (38).  The 
frequent mutations found in SSPE virus makes it difficult to discern whether these 
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mutations are a consequence of mutations accumulating in genes which are no 
longer essential for virus replication in the brain or whether they are in fact 
responsible for neurotropism.  By studying the fewer mutations in virus from SME 
brains it may be possible to determine which were responsible for the gain in 
neurotropism and learn more about the pathogenesis of the disorder.  Therefore, to 
characterize the brain virus, nucleoprotein, matrix, fusion and haemagglutinin genes 
from 4 cases of MIBE were compared with virus from acutely infected patients.  The 
brain virus was very similar to the acute epidemic virus (genotype B3) with mutation 
rates in brain of 0.87 per 1000 bases compared to the epidemic virus of 0.56 per 
1000 bases.  Most of the mutations in the brain virus were different for each patient.  
Interestingly, one point mutation in the fusion protein (L454W) was present in 2 
patients.  This region is thought to interact with an as yet unknown measles virus 
receptor in the brain and play a role in the fusion process (35). 
 
In measles virus from persistently infected brain the nucleoprotein gene typically 
retains its function as this protein is required to form intact ribonuclear protein 
complexes to enable the virus to move from cell to cell in the brain. The matrix 
protein, on the other hand, is usually highly mutated as this protein is not needed for 
replication in the brain (39).  This was not seen in the four SME patients and may be 
because sufficient time had not elapsed for mutations to accumulate in this gene 
before the clinical presentation of MIBE in our highly immunocompromised patients. 
 
It is probable that host factors were largely responsible for driving the disease 
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process.  Clearly, as not all severely immunocompromised HIV patients infected with 
measles developed MIBE, viral factors must have played a role (35). 
 
Identification of gaps and needs for further research. 
There is agreement regarding the need for urgency relating to vaccination 
programmes, which is by far the most effective way of preventing measles related 
complications.  This is of particular importance in South Africa with the large burden 
of HIV infection with many vulnerable patients.  There remains some uncertainty 
regarding the overlap between “fulminant SSPE” and SME and how this might be 
differentiated clinically and histologically.  Treatment of SME is an unmet need.  
Although there are case reports of Ribavirin being used, outcomes remain poor with 
death or severe neurological impairment in survivors.  In light of the novel findings 
from the MIBE molecular viral study relating to our patients (35), further research 
needs to be done to identify host and viral factors that predispose to SME in this 
highly contagious virus.   
 
Our case series involving eight patients with SME (40) was published in the South 
African Medical Journal in May 2011 and this manuscript follows in Part C. 
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2. Molecular characterisation of virus in the brains of patients with measles 
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sion proteitt ~(;)). Each M IB£ p~Mnt hrl a unique- pH· 
tcrn of mu-:.uions in on~ or n:ore of the- N, M. F and H 
gr·nN (T.\1)1(: 2;. l r; ""'' ' (fru· ,n e,.-1".<(:~ ~c'(Uf'1\t'.h~ ; t hM.-
' "'tl'e IS poi}T!lorpl'tisn:s prcscut in bn in "irus rd::,tr.-e to 
tl~o• $11n1h Afrio w (:()1l!'l•' 1l!'lt l'> lll")ll(~rt;l', ( l;i~t.! 'l}. 
.. • to C m d C to IJ mutations were- the- most conuuon 
l!l'J lalivru: pre:~·nl in Uw .:-pid.~'l!tic: •'irw; ~nJ lt\'I:R' al ~v ll-u: 
most frcq~nt in th~ brain \in:S. Th~ cakuL~tcd mutation 
frequency in br:tin "itu.s w-as O.Si PC'J 1000 nuclcoritks. 
T lti.,; \•;1s t:()ll .,;g ni i r;.1r11ly dim.~u'1ll lm ru II" • nuu;ll i .. rr I~ 
<'(HPI\t''/ t'lf thP t>pici>1Uk \'i rn( w hir h \~'\\' 0 !'-6 P"" IMO YTII · 
d t;lll il . .(!s (p -(U 9}. ln t .. n-:;liut h'· ,.r 1111• 1•) '>lh li( iluli(: t\..'> 
tlml 111;n1m.~el .. , •::odin~, "~gi(m'> i" l l11• h n1i" vim s, ,;; WC"TI' 
m•n·llyrwn~·mvu.l'. 'l11r: rn~ '<v i:...Li r: r~ivn lt\'llli Uw rwn 
codi•t& r~ion of the fusion gu~. 
Patients J a:td S had an identical L1 to G n:utation at 
J><,:s il inn J')l.t-1 ' " lhr r f,1'1:t.~ w h id 1 ~~~ r isr II• ;t f,101W 
$11h$t in lti t'·l\ hl t h <" tu~ it'ln p•x:~ il\. Of nMP, t hP 1~4\t' 
sulll'l l ih ll ilo)} \''1CI 1~ 1 1)1~~.~rll in 1 1~t.! l)S. uw:l \ 'h i '> (If palit.~lll 1 
(d ll'(jl'(l llurinf, 11(;n l~ rnl"~•lt.!S in fe'() ic,m :~ en91~~$ l'llrl it.!f. 
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It -do:~ : c ! lWI:Ic'W' io~.WA.'If JIJ IJ, 10:41 
ht :p:~/\Y\'I¥1,Yii \.I~)'.\-W111h.'.ll' :.:.0 lf j o),lti~!l 
~ :~..,con yt"\o(OI.~ c;.:~c.i 
Fhtllnl' 1 F i~·b!;¢n:lk II'H 1i t'-:U4ti.l tl' ud,;Jii.MJ.uli ..-id ow <ltlai,W~dltn: f h,~HJ ..... tiaim<~io;m oflh: n.od~1Uliili! 1i-uf IO&!.,;lk> 
•An;\ ~ p.~.r1n w~:w:"'" ,_.::~,.\ hflonll).rl :.lVI MII'IF durtns "'* t~~~~.,d.,u•pl5tlmlt (lfi'OO-'l-:MIOII'I ~ !!Jrtl:. '11+..-r(t' ~'11• ·,.,.~ 
ofc lher -nCMiesw.ng!"K.Ti:lei"J(~ 'tlne-«1 :'011' :"'e t(f! <.e"~f!rl:d.:t..l:mJe r d ~~ >1\':IQt<l: >n ,ooenc ., .. ~.mtcts. lxu~ap ·.~u .. csg~e.."fe­
.1" !1 i!~"" il 't.iW.o:d.: .lh: 11-U:lod ll l:' l = n-.. J1$ .U .: l,_l .b " .:IJI.Ij.l. . t.I!Jh. h .:o:Y.JI.hiiU)' Ih ." .. ~ .... ~ ur.u v I II .. - ..  
Discussion 
·n,.• 1111 11 -.l~-. \•in o .. "utiT111k in ~mrtll .<\ frim wn~ cllw lo 
~nn~ R~ :1 lm•)wn Alik:m el'l\•~· b W-'111. p•·~ 
il:ln., lmt•l.l i11h • ~'"·'lh Afr io t frum ! It<' 1111t lh wlt~ •n• IJt: 
going dtcubtton or mrulet virus or thli ge'IOI)~ hti 
b\'U: clo.:.:w:ll.•ntcJ ~n \'uriw :; Afri~11n -:;(.lun.lric; for 1:1an) 
)'farJ l10.11J. lnftc!lon spru:t • ... 1<1Ef>• lr. tt:e South Aiiican 
('ln['IUbtinn o{IIP "' ~~· h<'C·f'l inlll'l\lt\il)' Junly.c.i 11. (If r.~~· 
.;les "trus u.quel)(e!l liom aarte~· h fuctfd lndM:ltai; 
~h<I>.Mi thll t t hMt' WM 11 I~ IC"\'1"1 (1/ t;n \Mir Ylll'i ,llhil I)' it\ 
tho: ~pio.kr.li\ ·.ina. T hill i.'l t)pi~.sl of·.s .'li•:sl ~ ~ouno: inu...-
d \" 6nn wl1ich i-. (olluv,,..-1 h~ <.lil.."'oc' imuiun in n 111• t in1 
mw~ M~l<lti..'t< l l2,U). 
\'i'bt~ lr.vaston of the brah: darlr.; ac.ute er£3-lk:$ eroy 
()(<llr (1-1), Ml~t: Ill notm~f \'el')' t:lf"E. Most h!gN'j 
ir.ur.tm:>~compromiQ:'d patient$ "'1\o had acute en~les 
i1; lh i, I'Jii1l1•ni o d i<J nul <.1 • ...,1 .. )(1 M iRF.. Cll "(lli~ hulh 
vie·aJ ae:d bot.t f.lcton. pi~ .1 role ir, the dUeaR process. 
\'(<' ll l 1• tn(!d l iu kn .. wn li)()(ll t l~r• t'J'nd ic· r h ,• lwh•riiAio :!>. 
o i SSPE \'!nli. d.lb b r.ot thE Ctie fur MlBE ,frus. ':.!.1;: 
\Yi'l"l ' i r, lo•n'$1c•l l lo t~n Jitr•nu• l luo hrni ~; , ; ,.\!', in ..,.m'll' .,( 
tho:ie ca~s to detErmine Ju i lmU3dl)• to d:e epldEmk 
vinu. in ordtt to try to g;lill ins.ight ir.to the patho£er.~is 
oi thti notm3.11;' vel! nro: eMdll!.on. 
On IN ., :full~ the btair, vinu. waf; '.!(>~ s.imil<~" t~ the 
,u u l<• rtlillt 'tn i:· \•i ro" ' 11tis is in 1 <• llr-.:fll 111 whnl is li •m cl 
,.,ith s;p~; f9,L51 and aUo what ba' P~?•iludy beeel 
H1)1111f'>,l f.,r ,\ '. ltU: (1 \] . ,\oh lt,Jti:)ll nth~ \Yi'l"l ' simi~1r in 
brain ((J..$1 po:r 1000 ballet) to d:e ep!dernlc vir~ (0.56 per 
Hllll hlt~<S) . Hm,,'\'N', uf U11• Ul sllft(ll ituli" r..t> Uui <I<' 
cun-ed !r. t~ C<Xt!ng reg!ons of ger.es from bnln \rltw , 8 
- ·;. 1)(>1\-ot~Hv.yr.""''( (it\ f'rom p:111(<'!H M .w.ly 4- rof )!?. 
rrorn thE ep!demk \'lru!l). Thk ceuld. lm{ll:; d tbEr tbat 
<.ntn;> <;;>IA-ticot\ p ··;IUIII·;o \'>'l'lll. :vt it\ g (M\ rn~ v i n,lll. il\ thP 
br .Un ur I.Jwt u m uluiiun ~:.'1:-:.- nalh~ pr-ov .. 'lol; w1n cpo.•mtir.s.-
M,.,rt<JI":'' vin ,~ rl~<'$ 1\•'' \lf;llll lty 1\l'lit MI" <-,.'fn,~i ·dr it\ 
bn Un tie1.'1ue ;md il ill tlwu~ltl lhat ko:) mul.aiW!d ll'f.l) bo: 
n~ded to confe-r a IHUitl·,·lruler.t pher.ot'ype' l16, L? I. Be· 
<::11.1~ o.~f the m.s1~y toul:llionll found in S>l'J: v~ru~ . it 
II; dUlkult oo dtt('Lmle:~e \~ilk h. are resp:>ns.tble lOr r.euro· 
eru rHs rn .-:~J whkh nn • m 1orl'ly , . ,. . <1tll1l<lfi\l:'t:<'l ' .,( 
enuutior.s a::c.u.mu.lating i1t gen('s ..,1\icb are no !or.~r 
I'(IUI'tll illl fi t.- \'" " .. n1llk ntiom i ~< 1luo ht nin R~ :.11 \ll.l) ing 
tho: fev.oer matlt!OIU 1r. ·;trus from MlB~ bt:llm It IN}' 
ho• (ll lsl-i h!r• lo 1.11'11ornli rH' wh kl1 \YI'tl' R~[NW!<.il tlo• feu- llw 
p !r. In ruuro-crcptien. ln d'.ls swd)•, rw>st or lt.e mut3· 
tiont in the brai1t vie'Uf; \'>"l'l'e dilrwent !Or eadl pGtiif',t 
aod tart;etcl di!Rrent t;K.es. HO\'>"'e\'e!O oce pci1\t r.lUU· 
l i11n in lhr• f11~im; p ro l1oin, u u rdy J ,1S I \'t• '•ll,t.'> {lft~"' 'lll in 
:l p.~ti~nhl; ( I ;m•i ~). h i11. \1 1\lil:~ tro 1\:w.. ~ ~ ··h-'1 1\1"~ 
[NJI~nNJrphi(ltll i ~; tl""" ' <'in·•Jin ti n~ •, ;,,. .. lwn•1~a· it W,t.'> 
not pre;enc In the ·arute measle<~ ~quer.c:E of p·adEr.t 1. 
8ui.Jt k"UCil:-:.- .md tljpiupb .u: .lit.' , ICUlr.il. nun pohr 
3-miM ~ldt. Ho• ... <e":er:. tbt; sutm!tutkC'. t; not fl\'GW'td. 
P~!»'i-'ll y ir. :! I'IV>r.~"p p1'<1t~ir,, :1 t~ thP (lib li.litllrinl\ 
• ... ·ould. be llkef:; to ct..a~e d:e properdet oi tte protein 
r 1111. Thi.o;. ~.nh~cjtuti~n (,,II ~ it\ thl" l"lftT(I ,..,1. 11111' ri<~~YIAi t\ (I( 
IJ\~ fu..'lil..'t: pculo:~1:. :~ dj:~U'nl iv U1~ bo:pl.O!d r~po:at 8 d.om.sin 
(H'RB). Ay,1111 ~!~. ttl It i l t~h: '"T">.IIIt.ll n "ir..glt• "lll?ll • l•linn 
( 1'40-U) v,.t~ :.:~~o'llok fw r..: t.llv-•·~rul~r~ ci ;m s:w.: 
sa.:dn lrH bae:~bT enOOEI. Thl> ri'£l:m le> tbousht to Inter· 
3ct • .. ttt. lt:e ·as )~t unkr.owr. tne3..tles 'trus re:eptot lr. die 
bnin ar.~ f43)l; a rote ir, t t:e !U!il•: proc~" Tt:e indepeod-
1'111 pn...,>t:<t' .. r ,h i; n1n1n1iu11 i11 ?. (llt(il'll{ .. it~ i11 rrn~ir{',. 
There W<!:t'e rEtruti:<bl~ fN rnutaticr.e> in aU !Our of the 
f,<'fl<!l. 'o('li \l:'t:<'o11 fr .. nr tl~r• h otir. \'ir .,.._ In mu1"k~-. "ifiiS 
from peulitEnlt; lntectOO bl'3!r.,. both !r. hwn:.ns as well 'U 
in n11ioud n 'W II.IIh , llw nnclt 'O(l r> lto•i n f:11ll' l )(lil ~lll )' not,1i11s 
tts futKI!on :u thli pros.:-ln Is r«J.ulro:d to OOnn Intact 
ribor.uc~ar protcir, <.aupltx~ to enable the \•irue> to m::r.-e 
from oe!l t~ <ell In d.le Ualn 11J. Tho: m:~!rtl: (:'t'Ote!r.. on 
dte oth~r hllld. i; .aually hi(;hly r:.uul?d a' til¥; prt:Cein is 
nut I~<T'I.L 1 I fu.- r l'(llir uti" n i ~; tlw 1.-nin IJ \j ,',"' lj l't•r l..,.ps 
sufficient tim~ h3d r.ot ebp~ b e:w lltiO!t t t~ ao.:umu-
1,,11• in U:i" ~'l\1 ' h1.f11n' U11• ct illir ulpn(I<Ttt ,Jticm uf MIKI"; 
ln oor b!ghl}' Jmmuno-eomprornhed pl tltr.ts.. In 3 M1BE 
[llltit ·•Jis • .. +.u ~n'l ' 11 hita" ry .,( , Je·uh• nt111 ~l~s. tl~r• tnotli1m 
dme from 'KUte lnlectloo to onSEt d r.eurobgkal dhe3-le 
.... ':1( :\~II I () v,~(_ I I\ :-.!1 p.~ti~K. th<'l'<'> .... ~( :! u('lit:J 
neu~I::U dEteri!'H".ltb n after pre;.er.ut!.on, ....-ilkb f:'I'Cb· 
:11-ly r.>f1;>o·h\ dV> ~""""'' i tl'll'l\11 1\~ r nntl't:al d rro;>:'ldOIIt vil'\1( i1\ 
I.Jt-:.o bruir.. 
h \ .·nnrlu~n, it i1. pmh.,l'lll" tft.lt 1\(1~1 r, .·tn~ W('( <' 
l .st~d)· re.'lf'C'r .. ilok for o.hi,•in~ t~..: cliJo::&J< pco.o(.:~ ... HO' ... ~ 
ever, !Ult all uwrely lmr.lU!\Oo.C.otnpmtnle>OO 1-IJV pl· 
l.io:t:l~ infe..;t~ \vilb mu.'l!~.'l ,J ~ .. ~Iuped ,\'U~t:. 'd r .sl 
fu:ctore> als~ must ho\\-e played a rol~. l!ttdgu.lr:gl~ the 
htn i ~< vin l(l Y;ll.'> \'r·r y sinlil,1r 111 1lw ,.piclr•rn i1 virn " ~tnd 
did r.ot !how fewm previoody repot"tOO to be dlae-ac~ 
u •r it1o1 i1 1,1( Ml RF.. T lw tnllllll icm t'n•t J1 11 1'H'~ Y;lt.'> (limil,1r In 
o:p!d em!< ' 'lt'Ull, but stgnlitct~ r.tl~· tbo:ie muuuons ""'te 
tnOr<' li. 1-ly h • h<• n un t>;nnn, 1111111-1 .. A kr·~ fo rtrlin t'. W,t.'> 
lt.t t 2 pllltnu t~ the same L454\~· matatlor. ln d:e ru-
s.ion proteilt. 
 48 
1-'<:~t: -= rl'l( Vuubw .tow:uJ 21) 1].. 10::!83 
hrlr-i."'""'"'' '~'~'~~'J~ """""'mrrt<ru 11');1;n1 
··-: -{ :::-::~·1 
w.:....~:.· ... l ·t • ... ~· · V..- ;..., -;.KI~IlS . ..._ ...... ~ ... - ... _. -




, Yi r [-:;,':~, 






J ;,J -"" ' :1: llhylc.'!J"""""' e.-9,..,.., ,...1,..1 b y .., ;;.Jicl .. ,•1""·''"''9 -4'•" \ If I I~ "'-'" ""J'Jllllitoin 9"'"'" ,,. ,.,,..,. ..... , ,.;,.,., ~ ... - , f"'li.ol'l\ ..,;11> 
IW;ut 1'1\IIM~\ lrri(lnll).fl ;~nd Mll;.f. d llrlf'IS f~ ... -~"'' (>j'I~.Y!Io' d l'Om- Xl iO In S(ll.n'h IIIJtrn. ~-ft.trl'('t'<;rr ··~ fi •'lit•"''IT',..,Y.~ vh ~ 
fe~ifiCS '.o.'e'e r~evo:l fro-n t ' e NC!l Ger l nl:dat!:!e"! ~-.d .::~re ordated l:rj.t::<e&cn r .snte'l. ~~3"'l.Je5 9re:: ::r :'lilll'l J ~'!r. :re 
lr(' ,.,, ,"'!1:.- ' ""' IY·1"' <'lf n t H'f' Thl' v..r('~ l"''l":"Y :"f' r"l"lr<"lflr"Y r.- ·tv- f';,"'ulll'l'l)'rt<f;r : (': ;r. • -.w, r m -tw-~:If' 
Materials and methods 
M IRE rlil th•nb. 
J'211Er.ts • ... -e!'f tdenufl.eci ·as t ,a,•tng MUst: based on r; ptc3.1 
d ink31 ar\d r.u;;;nrtic rt>s::X\ 3!l Cl:' (~~r.:) ftr.dir.~ a' 
prt ,•IOuSI)' dEscttbOO (31 ·ar.d If measles ·,1!\1.'1 • ... "U 
<.ld(•rit•o l hy PCI\ in h rnit} tis~'" ' " r 1 r•l"l'h rnlilinll l i111i:.l 
(t 'St-'i. Ar. tr.· l':ooie dJagooslk nm~d Llf.l'U t u:>a)""'U 
ustd to amp{~ a 500 nudeotid~ rt'J,;r:letlt d the 
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IL------ ,1'#$1.1• H tl' 
I'#AA:tc.AA 
Flfl!lur f> l Nt t•ll).go> ll"'!!r U~\S"'""'::I IMI hyr.-!'lqhbftur .J(lll'll l'lt,l :tMiy'l ~ tlf fto.-1' llldr).tl (J1'1 ar~ tii.UJk 1.!1) gtt tlo>\ til tno>:I~1P\ >Jhlr. frl'ltn 
pllticnu riil 11c~ rnuslu tn r.ct10l'llltld Ml!ll:d t.:rin9 , ...._ rnu d u ePOemoc of li)~..:WlO tn So~.>tll Afriu. Ck'"tn"..e »e x r oe' d 
~U ~ l ll~!e Vi11,'>1,1:1 1VI*~'"'"' o: ~I .,_.,.10'1. lOIII .I It: ' IC!U<io:l iall<~dt.li. .,W.: 11. .: o: iutfw l o:tJ l)' <'f.l.r.~i<. 1 I .l ll .lo:llo. fk.ub ,l ~~· , ,!~,~a 
(lr r ; "l'!' "!'~; ., ~'?'!" :."f' r .1""'' ' 1 ,., rr ... rr .1M r · r .,"' l1'!" 7r ... !'l..- .. rr ... ~~"''~ f!••.,rrrf,.,r.:.l "l"I "!'W' f'-"lll "hr,\f)' r o;mr.-~ :.-; •Y¥¥:., r., 
ll ~o: ~ e 
nudeoprot~ln ger.e 113J. }.~essk; ·.1rus po;lttre braln or 
t 'Sf VJ;n; .~~·oiil o~blc for study un +l pu.liuaL'>. 
Patkr.t 1 •_.;ou a 2i ytar old woman .... oo llad a CD4 
r-n111H rof ~~ · ~t t i r.H• ro( :-.r n tP r.h'<'ld K . lvHOF n r ......- J'l<' • 
<u.rred 3 mont!:..; 3ftt:r ~ute mf':l.S-If$. Measles v!ru.; PCR 
.,. • .,., pro:-;iliYI" n o\ hr11 i1' b iror,.;y li<.:;t!C". Rr11 ii\ .. ·ir"~ w~o; 
~orup1w ... J wil b IH:Ut(.' •, ir O.Ili fror.1 l:lu(lcl lu.k(.'l: ~ toon lbu 
("'l"vi l"oll <.ly. 
l1.ati.enl l v:all a 14 ;ro: .ar o ld bv) v:l.h ;, <:JM ~ouut o f 1 
at time oi r.eutok@!cal prtl*r.ts11on. ThEre: wall no )".1!1· 
l.t..'t"!-' of a r:u.b. 'll<ill p.;~ tienl b:~cl r~o:i<>~cl m~:ulell 'l'.t'-"- ine 
(Sch·o~.m·o: n n lnj dur ln<1 a !ll.:hool rJa.:!l \ \Kd!Htlon o ru-
("' ign ~MlV' \Y\(>1\ Itt.."' Wror~' rli•li<'lll ('ll'f'SMlt,, ri,..,. MM."'!J'_"' 
virus PCR "A~s pos!tlve In CS!'. 
P,1tir••• $ ""•"' •' "1'1- y.,1t ulol "' " rn;m wlto o lt ~, (•l. o[K•l I)P 
ic~ Ml~t: ll ~tnpl.t..'lllll 3 '"' *"" ;,(l.c.'J ;,w k m~.alllo::~ inf~· 
I i••:.. H o•r ern (l)( lnl Ill pn~·nt.Jt i:)ll """'; ?.n 1V':o 1t -l~o; Yir(IS 
l"t'J{ • ... ·u poSIU"/e on pen t mortem br:ll:n W:iUE. l'Oil 
monem hlsl!l'lo-_y confimw:l M:OE. 
l'·aaent 4 , -..s 11 N year old woman . • 'IU3t: de,.·.: loped 
16 '~m~~ after ;K.ute- r:l'~f-let "A'hen tl<e CD4 <.Oll!\t W.\S 
I I. Mt•u-.,lt" \•iq 1s i>(:l~ w ,1:; I)I)Co.it i\'l' IU} p11s1 tnn r to •m 
bfain ti!ls!J(>. 
Pa~nu with acute measles 
M~u:o!c:; '>iruu ~amplt'a::J frc1:1 1a pcriphc ru.l ~ it(.' w.d t us 
urine or t1a<ld fum! S ~ttl}' Infected paden01 v.-s11 u.;.ed 
tn •' I'AAf;> ~ :;:-.uh Al.k :m ().A) ( ,.(11\ !l;l>ll!::\ l!> !1;"'}11;>1\o..,.. tn 
w~Jch lh bl':l!r. ' t ru.; wa; «ll'''lpo.rtd . 
l r. ,1<rMiriron, m.-.ul~ .. ·im <. l.·n m hie)()(! o·-niiN' tMi .v t lu-
lil:l~' o f .11.:1.1~ l:l t•o~ul(.'li I'! .IS .~~·.ill o~l:l~· fn nu Crl (.' puliual 
w hn <.\lh .,...qnl'n tly rll"w-lrofW'rl M m t. (("' tiC"IH 1) T h 4" 
bn~n \•iru~ o f lh i:~ p·.aLk nt ·,v:u cw:1p .ared · .. Hh l<o:r '-'"•1: 
~ute \1rus rather thar. the conaer.s:WI u quf!Ke. 
Hor.lri( ;,cid f''rtl'.JlCtiMI 
Total r.ud etc 3:<ld fur measles virus Kl'*'lll!~ wall l!\1· 
t inll)' ('$lr-, u to cl \ISing 1lw F.u -.,yrn.tt'. , m lm nlll l '<.l o•Kir nc'l l!f" 
(~io.'Vh:rio:ux, Mnt:) l' t:l ... ~k . l'n m:..:) .all po: r ru:muf:.o:· 
l(ln•r:-. in:;lr uo liOil\1- 5<~l o:; o•ttla,.ll l) I Ill ell IHJd c•ic· <Will 
w-as fXll'IICted f rom tl':e bratn or <..St' uslngtbe manual 
Qbg;m DN.~ r:l'lr.l kit with appropriate bufK>r11 fur tis-
sue :md c :w ex~n:tton as per manutacturer'l lniii'U(· 
t ion!l (Qia_;en, GrubU, Gennany). ~udei< add '~' 
r•hut-.1 ir• V() 111 d n tio n h<l( (r•r 11nd -.,w n •o l lll $()"(' unli l 
requited. 
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~41\: ~nc.( l'l!l.l.loY .A.IIrAI /~1 :., 10'-..!1!:. 
... u , ~l!"""'''";"''".rt: • • -.,.•, , ,,, ..._.,.,n rJ if.lll;; 
' l rW f'i11t• .. fln "lN!"l" r;w:r) F iil"'r~ 4 Pii,.WV•w"ti~ h " W"l"~utW by r.: jyi:W,.1 '1inir:9 ... u.lyW) uf Wl•o:A~nWIW n.'l.k'llp.to;~ ir) n~<~llio.. f~.t>ivn • rd ,_ ....,.J s l ool iiM 90''""' o>f . ,...,....,., .,;.,,.., ' " "n , .,.,;..,., ~ ,..;, h .,.. ., ... ·- ·"'• "'' ' "' rio ... , '""'' MIRF d m io"'J 1""' ,...,.""'~ <'Joi.oJo.oooio \ ol JOO"'-J Olll lfl "<N:!tl .\flk"ll, f~M .. 1'1"<1" T'!'ll .t'Y .-< rf n '!"' "l'\<q<JM"fUl~ll~;•~~r ... rrnr;,...1 fr,-.-n -.!" N('; r",t>-.::.•111' rtm~.n";r,1 :. .. 
ri'IC <..-ted bf OC«ll!C "~ n -nbers. &ooti :r:ap ·.a~cs o; "e:ter :"'illl"' • ~'!f. :we 1~ o::.r:ed .rt lh: "l iXeio"' the 1ree h e b-.: "Kh b'l;:hl:~re YOp:>ttC"l! x 
l '!"tv."'\rhm~rl~ra-: :.-; <t!"l.Y!'I flnftw- ~...-.-
eDNA S'fnthes ls and PCA 
R.'l.~ was CO!\'I.'Et'!ed inti em:.~ us.i.ng the REw rtAid Fil.~t 
Sln n:J illl'>A llp:tl;,c, a k it ft'ut~1:t:u Lifo: Scio: l:(;es~ ;:rnd 
r.m.<bm t:e:x:une:l'!l. Stle:lt:; U ~I RNA v.:aB lno.tbated • ... 1tt. 
I 1•l Ul\r{n m l~unM' •u w lio><l 'l.ctith ki1 ,1t !=:0'(" tn1· :l r.l i · 
r.utei :~nd thEn coolEd to '3,.C bEfore tht addk!or. ~ 4 !II 
5 l( rro:cti:r, bulla ; 1 p.l Ribolock JU.:'-lse ir,bibitor (20 Ut 
11l), J. 111 10 c livi d~TP 111i ~ nq l l pl Ro"\'1 'i'IAicl M IYh d V 
rEwne ln!Ul.:riptate (200 l't~tb i.r, a !Y:aJ ?f) p.l r&..:tion 
\OOI!omw T lw miU (III ' wn' irrl '(ll• ll('fl 111 ~?"(' !'u r 'CII'l m in 
anJ tbo: :.:.r.:lior. l.c.'n nir.dal. IY1 hut~r.s to N C.; M > •:ti· 
r.utt"'\. ,·fJ'lA -...(l,.;!;tn,.....; 111t ?.(1'(" llllri rJ"]_ni n-tl . 
'l 'lw O(II11Jlil'l o• lllfi'I ('IOilll)h~n ( 1\.) , tn ,ll ri~ (M ) , f11sion 
( f ) :tr.d l'.aem:lgglutlrJn. (H) iler.es ..,..H~ amplltled with 
ll ritn('l'l; d ('$1 ril:r•ol b y Til l ir•1 ~r • l ,.!, j1 1). In o ~·:;. "' •,dwr•• 
there ...,':l.i no w plli'kadon. after cue round of PCR. 
r.es tro primEn detli;;ned for tb i~ stud~ '<1.\!:re w;«<, 
(Addmonal ftle 1: T! ble Sl). 
~~usks ,.,ltw fro)m a (Xltkr.t •,v!th :~ cute me3.iles '.o>ti 
used as dte p-:>~iti~ cor.trol tbr all tl<e PCR a Mays. PCR 
:amplicold ".>~: re ~rK'nrteoJ u:~in~ 61'1 cO.'U • :anJ Su· 
p.e:rtherm Taq 0 :\IA p.:>l:.me:ras.e (IMl Holdtr.ss. LIK) 
wilt!. tft.p (nl!nwir.e P('llt r}'d i"z rnntli li <m~ ~r. i rl iri!l l Jt>. 
r.:t tundon. step or 3 min. :tt 'JS"C, foUo";.:d ~ 40 c~·dn 
of auplilication (l::i stc at 94-'C, :1.> s at 7.J'C and .U s 
'J ,J"( ') fuHmo<r•ol loy 7 mi n nrl '? !:{ , '11u• nr~'>h 't.l P( ,R '.i'U' 
~rt"..'lt·med usi.q~ the same ")\:ling cor.diti:m~ but witb 
11n i rr or o-a-..• in ,. ,.. llnrro -..jio~ ll'mcx•r nHir o• I n !i!i 'C nm l 
:J j.d o u tu produd. 
P( :R ,..-Mum -... .... r,. <'lrttr~"'~~ thrnug h ?.S •'&" 
f )(«' t<'~ 11rrcl -.iS\III I iX~'fl h;, (ofhi:.l i(lnl lmom it l (• ' lninint', ••:d 
lJV lllu.mtnx!or •. 
~uendng and plwylogenHk u dysh 
PeR pr o.iucts 'toW~ SEquet..:Ed di'«dy h both direc1;i)r.s 
v,u b ptt'l'leiS wed for t'U t ·arnpllflc3Uor •. 'I 'M ~>~g~·.:: 
1 ablo:o 2 N~o~d o>ot ido> and ,vnlola ;a.d d d iffo:oo'l>neow; In lh o> nw.lo>n!)o'llll o>lo, lNI, oll'l.lltrili (MI, rud e.n (f ) ;w~d h..Wtll'l ;t.glu t on il'l (H) 
gen-es boet\\'H tl tile ~11th Afrk at1 measles consens~o~s 113.1 se<~.utn<e illnd b•ain virus froo1 4 1)at ients with M16E 
61'111: H.,~l~:~.>ti dt uW lilm H..,,Jo:utilk 
s;,c...., ?.,,, 
r, sn A A 
""' 
"" ,.,
































l\rninu .Nd pv,;tj..,,, ArnLw ... Ud 









•/t l (' 








~""~h ...... _. ....... ...,, 101-~,i'<Jf • I'Ol.,l l. i..,U IM'.II"I.l.~ pv..-,":J,M~ <>I'Unt ... . ·/t! .-. ....... ~ IOno •4c.c.• ~>.><:IMl ... thot ., .,. . 










PART D:  APPENDICES 
1. Data collection form 
Data collection form 
Patient number:   
Medical folder number: 
Age: 
Gender:   
Medical comorbidities:   
HIV status: 
Known HIV +ve at presentation: Y/N 
On antiretroviral Rx at presentation: Y/N 
CD4 nadir: 
CD4 at presentation: 
History of skin rash or documented measles infection: 
Time between skin rash and presentation: 
Other opportunistic infection:  
Pneumonitis at presentation: Y/N 
Presenting symptom: 
Seizures? (if so, state if focal or generalised or both):                                
Visual impairment/blindness?:  Y/N 
Hearing impairment/deafness?:  Y/N 
CSF biochemistry and cell count:   
CSF measles PCR +/- IgG IgM: 
Urine measles PCR: +/-/nd 
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Post-mortem histology:   
Outcome:  



























3. Human Research Ethics Committee approval 
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